课题基金 / 基金详情

Development of Optimized Reversible Pin1 Inhibitors to Block Multiple Cancer-Driving Pathways and to Disrupt Immunosuppressive Tumor Microenvironment

Development of Optimized Reversible Pin1 Inhibitors to Block Multiple Cancer-Driving Pathways and to Disrupt Immunosuppressive Tumor Microenvironment
开发优化的可逆 Pin1 抑制剂以阻断多种癌症驱动途径并破坏免疫抑制肿瘤微环境
批准号：
494870
负责人：
Lu Kun Ping
金额：
$7.29万
依托单位：
University of Western Ontario
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
已结题
起止时间：
2023-09-01 至 2024-09-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=494870&lang=en
关键词：
Cancer Immunotherapy Cancer Signalling Cancer Therapeutics Exploratory Translational Cancer Research Innovative Pharmacological Agents Molecular Targeted Therapies Multiple Cancer Pathways Overcome Cancer Resistance Pin1 Inhibitors Triple-Negativ

项目摘要

项目成果

Lu Kun Ping的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Molecularly targeted therapies against specific cancer pathways and immunotherapies against immune checkpoints have revolutionized the treatment of some cancers. However, most cancer patients have yet to see the benefits because their tumors have multiple
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identification of Novel Disease Drivers, Therapeutic Targets, and Biomarkers of Sepsis
  • 批准号：
    484160
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Lu Kun Ping
  • 依托单位：
    University of Western Ontario
Identification of Novel Disease Drivers, Therapeutic Targets, and Biomarkers of Sepsis
  • 批准号：
    494277
  • 项目类别：
    Operating Grants
  • 资助金额：
    $7.29万
  • 财政年份：
    2023
  • 负责人：
    Lu Kun Ping
  • 依托单位：
    University of Western Ontario
海外基金